Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$2.22 0.01 (0.45%)
2/9/2010 4:00 PM

Anadys Pharmaceuticals, Inc. (ANDS)

CAPS Rating:
**

A biopharmaceutical company committed to the discovery, development and commercialization of small-molecule medicines for the treatment of hepatitis and cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

ANDS doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

34 Outperforms
12 Underperforms
 

All-Stars

15 Outperforms
5 Underperforms
 

Wall Street

9 Outperforms
0 Underperforms
 

Members bullish on ANDS are also bullish on:

Members bearish on ANDS are also bearish on:

Ticker Tags

Growth (1902), Defensive (1457), Biotechnology (220), Healthcare (711), Aggressive Growth (860), Micro Cap (4701)
Suggest a tag

Anadys Pharmaceuticals, Inc. At A Glance

Current Price: $2.22
Last Trade Time: 2/9/2010 4:00 PM
Open: $2.19
Previous Close: $2.21
Daily Range: $2.15 - $2.32
52-Week Range: $1.44 - $8.43
Volume: 502,057
Market Cap: $82.83M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ANDS VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

5

Anadys Pharmaceuticals, Inc. (ANDS)

Avatar zzlangerhans (99.64) Submitted: 4/23/09 11:08 PM

This is kind of a tough one. The street took the news about the rash in a really bad way, while the company underplayed it dramatically in their PR to the extent of stating the drug was well tolerated and no serious adverse events were reported, although ...

Given the strong antiviral effect of the...More

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

2

Anadys Pharmaceuticals, Inc. (ANDS)

Avatar OptionsWizard (91.56) Submitted: 3/30/09 8:04 PM

This climbed too high too fast.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 4 of 4  

Show Pitch Replies

Recs

0

 (ANDS)

Avatar jasenj1 (91.17) Submitted: 4/24/09 8:24 AM : Outperform Start Price: $3.58 ANDS Score: -63.92

Following BravoBevo

Report this Post Replies: 1 | Reply | Permalink

Recs

5

 (ANDS)

Avatar zzlangerhans (99.64) Submitted: 4/23/09 11:08 PM : Outperform Start Price: $3.44 ANDS Score: -62.79

This is kind of a tough one. The street took the news about the rash in a really bad way, while the company underplayed it dramatically in their PR to the extent of stating the drug was well tolerated and no serious adverse events were reported, although ...

Given the strong antiviral effect of the drug and the early stage of development, I think it is highly likely that Anadys will rebound from current lows. The weak cash position is a concern as the company will need either dilutive financing or a development deal for ANA598 on unfavorable terms.

The bottom line is how dangerous the rash effect is to the drug's continued development and marketability. Given the nasty side effects of approved treatments for hep C I think Anadys is worth a green thumb at least back up to 4.5 after which the risk/reward ratio will likely turn unfavorable again.

Report this Post Replies: 1 | Reply | Permalink

Recs

2

 (ANDS)

Avatar OptionsWizard (91.56) Submitted: 3/30/09 8:04 PM : Underperform Start Price: $6.98 ANDS Score: 104.37

This climbed too high too fast.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ANDS)

Avatar CroweByrd (< 20) Submitted: 12/04/06 2:57 PM : Outperform Start Price: $5.04 ANDS Score: -36.30

Why not? it's a bargain. It has plenty of good products in the developmental pipeline and is experiencing a changing of the guards with a new CEO who has been battle hardened..

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 4 of 4  

Wall Street

Results 1 - 9 of 9  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackOppenheimer 81.36 04/14/09 Outperform NS $6.38-65.20%+27.41%-92.61
TrackWedbush 66.12 04/02/09 Outperform NS $6.72-66.96%+28.93%-95.89
TrackLeerinkSwan 92.83 03/20/09 Outperform NS $6.19-64.14%+37.55%-101.69
TrackCanaccord 86.15 02/09/09 Outperform NS $5.99-62.94%+25.70%-88.64
TrackPiperJaff 85.79 02/09/09 Outperform NS $6.18-64.08%+25.47%-89.55
TrackThinkEquity 64.82 01/27/09 Outperform NS $4.90-54.69%+29.70%-84.40
TrackRodmanRen < 20 01/26/09 Outperform NS $4.70-52.77%+30.53%-83.30
TrackJMP 71.98 01/20/09 Outperform NS $5.45-59.27%+31.62%-90.89
TrackSusquehanna 74.67 01/24/07 Outperform NS $4.81-53.85%-20.40%-33.45

Results 1 - 9 of 9  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD03 78ms